In addition to these AML subtypes, AML characterized by a granulo-monocyte progenitor (GMP)-like phenotype also displayed sensitivity to Bleximenib; these cases included leukemias bearing CEBPA mutations [115]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.